Nuvo research is definitely one of the most undervalued

New Post Public Reply Private Reply Replies (1) Message Board
whatisthecolorofmone

Nuvo research is definitely one of the most undervalued stock in the Biotech Sector .

FDA approval for the "Best in Class topical medication" on March 4 ,2013 . Nuvo has already a fantastic Partnership with Big Player Covidien in place .

Nuvo will hit profitability this year with 2 product launches in 2Q 2013 .

Upcoming Milestones 2013 :

March 4, 2013 PDUFA date for Pennsaid 2%

Q2 2013 worldwide launch of Pliaglis by Galderma

.....

My Target is $0.30++ by mid 2013 !GLTA

Nuvo Research (NRI.TO)

Market Cap : $ 36 M

Cash: $ 12 M

Price 0.065 $

Presentation Jan 2013

http://www.nuvoresearch.com/investors/documen...ns/2013-.. .

-Specialty pharmaceutical company (TSX:NRI)

• U.S. based Pain Group

• Germany based Immunology Group

- Growing revenue with 3 approved pain products:

- Pennsaid®: topical NSAID for osteoarthritis, partnered with Covidien for

U.S., targeting $8B oral NSAID market

- Pliaglis®: analgesic peelable cream, targeting global cosmetic and

dermatology markets, partnered with Galderma, worldwide launch

commencing Q2 2013

- Synera®: analgesic patch for needle stick pain, targeting U.S. dialysis and

infusion centers

- Potential game changing immunology platform with positive Phase 2

results in allergic rhinitis

Nuvo Research Inc. is a publicly traded (TSX:NRI), Canadian specialty pharmaceutical company, headquartered in Mississauga, Ontario. The Company is building a portfolio of products for the treatment of pain through internal research and development and by in-licensing and acquisition.

The Company's Pain Group, located in West Chester, Pennsylvania, is focused on the development and commercialization of topically delivered pain products. The Company’s product portfolio includes Pennsaid®, Pliaglis® and Synera®.

Pennsaid, a topical NSAID, is used to treat the signs and symptoms of OA of the knee(s). Pennsaid is sold in the United States by Mallinckrodt Inc., the pharmaceuticals business of Covidien, in Canada by Paladin Labs Inc. (TSX LB) and in several European countries.

Pliaglis is a topical local anesthetic cream, which is FDA-approved to provide topical local analgesia for superficial dermatological procedures. The Company has licensed worldwide marketing rights to Pliaglis to Galderma Pharma S.A., a global company dedicated to dermatology.

Synera is a topical patch that combines lidocaine, tetracaine and heat, approved in the United States to provide local dermal analgesia for superficial venous access and superficial dermatological procedures and in Europe, for surface anaesthesia of normal intact  skin . Nuvo currently markets Synera in the United States and its licensing partner, EuroCept International B.V., has initiated a pan-European launch of Synera (under the name Rapydan®) in several European countries.

Through its subsidiary, Nuvo Research GmbH, based in Leipzig, Germany, the Company is also developing the compound WF10, for the treatment of immune related diseases

http://www.nuvoresearch.com/investors/documen...y_2013.pdf

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 7

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 25

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 35

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 60

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 97

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading

Top 5 Most Recently Viewed Articles

DocGo Inc. Faces Legal Scrutiny Amid Allegations of Misconduct

Updated Category News Views 303

Continuation of Investigation into DocGo Inc. Former Louisiana Attorney General Charles C. Foti, Jr., Esq., is continuing the investigation into DocGo Inc. The firm Kahn Swick & Foti, LLC (KSF), where Foti serves as a partner, is actively pursuing key information related to the conduct of the company’s officers and directors. This scrutiny comes in response to serious...

Continue Reading
Comprehensive Metabolic Panel Testing Market Growth Insights

Updated Category News Views 171

Overview of the Comprehensive Metabolic Panel Testing Market The Comprehensive Metabolic Panel (CMP) testing market is witnessing significant growth, driven by an increasing focus on preventive healthcare and early disease detection. This sector is estimated to expand remarkably in the upcoming years, projected to reach USD 24.48 billion by 2032 with a robust compound...

Continue Reading
Celebrating Future Legal Talents with Ándale Scholarship 2025

Updated Category News Views 244

Two Future Legal Leaders Awarded 2025 Ándale Scholarship At a recent ceremony that brought together the finest minds in the legal profession, two bright law students were honored with the esteemed Ándale Scholarship for the year 2025. This award, conferred by Gastelum Attorneys, is a symbol of recognition for outstanding achievement and potential in the field of law....

Continue Reading
Arkstone and Neslab Join Forces to Innovate Healthcare Solutions

Updated Category News Views 330

Arkstone Partners with Neslab to Transform Healthcare in Peru Arkstone Medical Solutions has forged a pioneering partnership with Neslab, a prominent medical technology firm based in Peru. This collaboration aims to broaden access to precision-guided treatments for infectious diseases across the nation. By leveraging cutting-edge antimicrobial stewardship tools and...

Continue Reading
Opportunity for Investors to Explore NeueHealth's Status

Updated Category News Views 155

Investors Encouraged to Join the Investigation of NeueHealth The Schall Law Firm, a leading national shareholder rights litigation firm, is currently investigating claims on behalf of investors in NeueHealth, Inc. (“NeueHealth” or “the Company”) (NYSE: NEUE). The focus of this investigation is to determine whether the directors and management of NeueHealth have...

Continue Reading